Related references
Note: Only part of the references are listed.Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement
Vanessa Smith et al.
JOURNAL OF RHEUMATOLOGY (2013)
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database
Florian M. P. Meier et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab
Wan-Hee Yoo
RHEUMATOLOGY INTERNATIONAL (2012)
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study
V. Smith et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic
F. Perosa et al.
JOURNAL OF INTERNAL MEDICINE (2010)
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Dimitrios Daoussis et al.
RHEUMATOLOGY (2010)
Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature
Dimitrios Daoussis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
Silvia Bosello et al.
ARTHRITIS RESEARCH & THERAPY (2010)
B Cell Depletion With Rituximab in Patients With Diffuse Cutaneous Systemic Sclerosis
Robert Lafyatis et al.
ARTHRITIS AND RHEUMATISM (2009)
Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab
D. McGonagle et al.
RHEUMATOLOGY (2008)
BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice
Takashi Matsushita et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis
Laszló Czirjak et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis
Y. Hitomi et al.
TISSUE ANTIGENS (2007)
B cell infiltration in systemic sclerosis-associated interstitial lung disease
Robert Lafyatis et al.
ARTHRITIS AND RHEUMATISM (2007)
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
U. A. Walker et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity
Manabu Fujimoto et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2007)
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
D. Khanna et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis
Minoru Hasegawa et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Elevated serum BAFF levels in patients with systemic sclerosis - Enhanced BAFF signaling in systemic sclerosis B lymphocytes
T Matsushita et al.
ARTHRITIS AND RHEUMATISM (2006)
Fibrotic disease and the TH1/TH2 paradigm
TA Wynn
NATURE REVIEWS IMMUNOLOGY (2004)
B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse
N Asano et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Altered blood B lymphocyte Homeostasis in systemic sclerosis - Expanded naive B cells and diminished but activated memory B cells
S Sato et al.
ARTHRITIS AND RHEUMATISM (2004)
Systemic and cell type-specific gene expression patterns in scleroderma skin
ML Whitfield et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
J Boye et al.
ANNALS OF ONCOLOGY (2003)
Quantitative genetic variation in CD19 expression correlates with autoimmunity
S Sato et al.
JOURNAL OF IMMUNOLOGY (2000)
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas:: results of a phase-II study of the German Low-Grade Lymphoma Study Group
M Feuring-Buske et al.
ANNALS OF HEMATOLOGY (2000)
Share Paper
